English (United States) 
Polish 
French 
German 
Swedish 
Italian 
Spanish 
Czech 
Slovak 
Indonesian 
Hungarian 
Romanian 
Portuguese 
Bulgarian 
Lithuanian 
Latvian 
Slovenian 
Danish 
Finnish 
Estonian 
Dutch 
English (UK) 
Arabic 
Japanese 
Korean Selank vs. Adalank: What Are the Differences and Which Peptide Has More Scientific Evidence?
Proven anti-anxiety peptide versus its potential next-generation successor – the same family of compounds, but a completely different level of scientific evidence
What is Adalank and how does it relate to Selank?
Adalank can be described as „Selank 2.0” – a newer, modified version of the same compound. Both peptides were developed in the same Russian research institute and are derived from the same natural molecule – tufts, which participates in communication between the immune and nervous systems.
The creators of Adalank made minor modifications to Selank's structure to potentially increase its stability in the body, improve its targeting in the brain, or prolong the effect of a single dose.
However, the most important difference concerns the amount of available scientific data. Selank It is a well-studied and approved drug, the effects of which have been evaluated in over 15 human clinical trials. Adalank The drug is in the experimental stage – almost all available data comes from animal studies. It has not been approved in any country, and no significant human clinical trials have been published. Both compounds are therefore at completely different stages of development.
How do they differ in terms of construction and operating durability?
| Feature | Selank | Adalank |
|---|---|---|
| Peptide structure | 7 amino acids; structure fully described and well-documented | Also based on tuftsine, but it contains modifications potentially designed to slow down its breakdown in the body; the exact structure has not been widely published in international literature |
| Stability in the body | The parent molecule breaks down after about 2 minutes, but active fragments can persist for 3–4 hours | Likely more stable according to design specifications, which could reduce dosing frequency, but this has not been confirmed in humans |
| Method of administration | Nasal spray (0.15% solution) with fixed dosing regimens | Presumably also administered nasally, but official dosing in humans has not been established |
How do they affect the brain?
| Feature | Selank | Adalank |
|---|---|---|
| Regulation of the nervous system | Gently supports the natural GABA-based calming system without the risk of sedation and addiction characteristic of classic sedatives; confirmed in clinical studies. | It likely works similarly, however, preliminary data suggest a more selective impact on the GABA system and potentially an even lower risk of sedation; the data come exclusively from preclinical studies. |
| Protection and development of nerve cells | Well-documented impact on increasing BDNF and NGF, supporting memory and learning | Animal data suggest similar or potentially stronger neuroprotective effects; one rodent study showed better brain tissue protection after an ischemia-like event |
| Effect on mood | Mild effect on serotonin and dopamine pathways, which may translate into a subtle mood-enhancing effect | It could be more targeted towards anxiety reduction and have less impact on mood; the data is still very limited |
| Effects on the immune system | Clear immunomodulatory properties stemming from tuftsin origin | Because the basic structure of tuftsin has been preserved, similar effects are expected; however, this has not yet been investigated. |
| Stress resistance | Slows the breakdown of natural substances that support emotional stability, increasing resilience to stress | It likely shows a similar effect due to maintaining the basic structure, however, there is a lack of specific research for Adalank. |
What Does Research Show?
| Feature | Selank | Adalank |
|---|---|---|
| Human studies | Approximately 15 clinical studies in Russia and Ukraine have shown a significant reduction in anxiety in people with anxiety disorders and stress-related problems. | Practically no published clinical trials in humans; single preliminary reports have not been widely published in international literature |
| Animal studies | Extensive; confirming the influence on neuroprotection, GABA regulation, neurotransmitter systems, and the immune system | A moderate number of studies; in standard rodent models of anxiety, Adalank showed effects comparable to or slightly stronger than Selank. |
| Security profile | Good tolerability in all published clinical trials; no serious adverse events; limited data on long-term use | No safety data in humans; toxicology studies in animals are promising, but do not replace clinical trials. |
| Regulatory status | Approved in Russia and Ukraine for use in anxiety and stress-related fatigue | Not approved in any country; not yet at the stage of seeking registration |
| Dosage | Established: 400–600 micrograms intranasally, 1–3 times daily | There is no validated dosage for humans; all uses are experimental. |
| Availability | Commercial product in Russia and Ukraine; otherwise mainly available as a research peptide | For research purposes only; very limited availability |
Potential Advantages and Limitations
What could Adalank potentially improve over Selank?
If structural modifications prove effective in humans, Adalank could offer:
- longer duration of action and less frequent dosing,
- more selective anxiolytic action,
- even lower risk of sedation,
- stronger neuroprotective properties,
- Maintaining beneficial immunomodulatory properties.
However, it should be emphasized that these are design assumptions, which have not yet been confirmed in clinical trials in humans.
Why is Selank a Safer Choice Today?
Selank has:
- proven clinical efficacy,
- well-known safety profile,
- established dosing regimens,
- approval for use in Russia and Ukraine.
Adalank, on the other hand:
- does not have pharmacokinetic data in humans,
- There is no established dosage.,
- does not have clinical safety data,
- has not been adequately studied in humans.
At the current stage, it should be treated solely as experimental research compound.
What Research Is Still Needed?
| Area | Selank | Adalank |
|---|---|---|
| Most urgent research needs | Replication of Russian studies in accordance with international standards and long-term safety studies exceeding 6 months | The first human studies to determine safety, dosage, and pharmacokinetics |
| Comparative studies are needed | Direct comparisons with SSRIs and Afobazole to determine its place among available therapeutic options | Direct comparison with Selank in humans, as Adalank was designed as its potential improvement |
| Mechanistic achievements | Minor gaps regarding receptor adaptation during long-term use | Confirmation of greater selectivity towards the GABA system and increased stability, which are currently based solely on preclinical data |
Selank is a verified and approved preparation with a solid foundation of human clinical trials. Adalank constitutes a promising development of the same line of research, but currently remains only at the laboratory stage.
The choice of Adalank over Selank can be compared to choosing a prototype car over a model that has already passed road tests – the prototype may look promising on paper, but data confirming that it will indeed meet expectations is still lacking.
Disclaimer
The content is for educational and informational purposes only and should not be interpreted as medical advice, diagnosis, or treatment recommendation. Consult with a qualified healthcare professional before starting, stopping, or changing the use of any medication or supplement.
Ani Selank, and Adalank have not been approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), or most other Western regulatory bodies. In particular Adalank has not been approved in any country and does not have established human safety or dosage data..